Connect with us

BUSINESS

Halo Collective Inc (OTCMKTS:HCANF) Gets An Entry Into The FTSE Russel Index: Bophelo Completes First Cannabis Flower Sale

Published

on

Halo Collective Inc (OTCMKTS:HCANF) finds a place in the FTSE Russel Index. With this accreditation, Halo Collective will improve its exposure to the cannabis market with effect from March 19, 2021.

FTSE Russel, a wholly-owned subsidiary of LSEG (London Stock Exchange Group), provides index offerings for the financial markets worldwide. It is used as a benchmark to measure the performance of investments.

Bophelo completes cannabis flower sale

Bophelo Bioscience & Wellness (Pty) Ltd, a Halo Collective subsidiary, completed the first sale of its cannabis flower to Lesotho, Africa-based licensed exporter and producer.

The demand for license-to-license business in Africa expects to reach $7.1 billion by the year 2023. Bophelo is well-positioned to benefit from this opportunity by cultivating premium-quality flower and selling at economical rates to the patients in Africa.

The per gram cultivation cost of Bophelo is $0.33. It is definitely in profit because the purchaser acquired two lots of different strains at a per gram cost of $2.0.

Signs a pact with Nature’s Best Resources LLC

Halo Collective signed a definitive accord with Nature’s Best Resources LLC. The deal allows Halo Collective to become a vertically integrated cannabis company and engage in the extraction, manufacture, cultivation, and distribution of high-quality cannabis products.

As per the terms of the accord, Halo Collective will acquire a 100% stake in Nature’s Best in exchange for its 44.047 million common shares.

Nature’s Best solventless cannabis concentrate gained immense popularity in California and Oregon in the past few years. The company also engages in rosin variants like caviar, taffy, and ice water hash.

The honey-like texture of Rosin is different from other concentrates because of its unique extraction process and possesses the same flavor and effects similar to traditional flowers. In the concentrates segment, live Rosin is growing rapidly according to the evolving trends in the cannabis industry.

Nature’s Best also manufactures high-quality hash byproducts, which can be sold to blend with pre-rolls, beverages, and edibles.

The sales of rosin concentrate increased to $17.78 million in Oregon in 2020 from $7.36 million in 2019. Also, it recorded sales of $24.81 million in California in 2020 compared to $12.49 million in 2019.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

BUSINESS

Trulieve Cannabis Corp (OTCMKTS: TCNNF) Reopens North Port Dispensary, Formerly Harves House of Cannabis

Published

on

Trulieve Cannabis Corp (OTCMKTS: TCNNF) has announced the reopening of a North Port, Florida dispensary. This dispensary located in the Sarasota area is the 92nd Trulieve location in the state and was previously named Harvest House of Cannabis.

Trulieve reopens North Port dispensary. 

When the North Port site reopens as Trulieve, it will greet Harvest patients with the same devoted personnel and high-quality service as when it closed for renovations and rebranding. Trulieve announced the completion of its purchase of Harvest Health and Recreation Inc. on October 1, with all Harvest dispensaries in Florida closed for rebranding to Trulieve. Throughout the month of October, the Company will continue to reopen Harvest sites across Florida.

The company is inviting the community to celebrate the reopening of its dispensary with all-day specials and swag giveaways. On launch day, all patients, from newcomers to long-time Trulieve patients, will be eligible for a 25% discount at the North Port facility.

Patients will find the largest assortment of CBD and THC products in Florida, including edibles, concentrates, smokable flowers, tinctures, vaporizers, topical creams, and more, in stores and online. Trulieve also provides home delivery throughout the state, as well as web-based ordering and in-store pickups.

Products available online and in-store 

Trulieve’s whole product portfolio is available for online orders to aid patients with ordering, with in-store pickup or home delivery options available across the state depending on customer preference. In addition, Trulieve provides complimentary 30-minute virtual consultations with a Trulieve expert to assist with product, device, or doctor’s suggestion questions. Appointments are available on Trulieve’s website and open to all patients, even if they are new to medical cannabis or those searching for new therapeutic choices.

The company is keeping an eye on the COVID-19 situation and is committed to limiting the virus’s spread. Trulieve requires all staff, regardless of vaccination status, to put on masks in addition to following strict cleanliness and safety measures.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

BUSINESS

ILUS International Inc. (OTCMKTS: ILUS) Announces Award Of a $1 Million Contract For Phase 2 Burj 2020 Project

Published

on

ILUS International Inc. (OTCMKTS: ILUS) has announced that BDC Fire which it acquired on April 12, 2021, which had received three contract awards estimated at $1.5 million, has now received a $1 million contract for phase 2 of the Burj 2020 Project.

BCD Fie receives another $1 million contract 

BCD Fore had previously received a contract for fire systems installation for the Burj 2020 Tower in Dubai. The company started work on the project inQ3 2020, and the contract value for the phase is around $1 million.

The company is committed to completing the project and upcoming projects, and as a result, it is recruiting an additional 45 technicians and salespeople. Hiring more technicians puts the company in a position to apply for the lucrative A-level license for installation, supply, and maintenance of fire systems in industrial, residential, and oil fields.

ILUS Managing DirectorJohn-Paul Backwell said, “BCD Fire has achieved so much since we acquired it earlier this year and the award of this next phase of the Burj 2020 project is reward for the progress made by the ILUS and BCD teams. Obtaining the A-level license will rocket this acquisition to a whole new level. There has also been overwhelming interest from regional Fire Safety Training Companies in our new Virtual Reality Fire Extinguisher Training Courses which are being launched this month.”

FireBug and TVC received numerous purchase orders 

CEO Nick Link stated, “ILUS just closed out its best quarter yet and we are looking forward to releasing an update on this in the next week or so once the team has finished consolidating the figures. FireBug and TVC have received several purchase orders during the 3rd quarter and they have been making excellent progress, but we have felt it best to provide updates on the more significant deals in the region of $1 million and upwards or noteworthy clients.”

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

BUSINESS

Roche Holding Ltd (OTCMKTS: RHHBY) To Present New OCREVUS and ENSPRYNG Data at ECTRIMS 2021

Published

on

Roche Holding Ltd (OTCMKTS: RHHBY) has announced that it will present new ENSPRYNG (satralizumab) and OCREVUS (ocrelizumab) data during the 37th Congress of the European Committee for Treatment and  Research in Multiple Sclerosis.

Roche to present ENSPRYNG and OCREVUS data 

The data comprises 38 abstracts showing new long-terms safety and efficacy data for ENSPRYNG and OCREVUS and the company’s ongoing efforts to assess COVID-19’s impact on people living with multiple sclerosis. More data will shore enhanced scientific understanding of NMOSD and MS in various patient populations, ensuring access to treatment.

Roche’s chief medical officer and global product development head Levi Garraway, said, “The longer-term efficacy and safety data for both OCREVUS and ENSPRYNG reinforce e the impact of these treatments- by significantly slowing disease progression in MS and by preventing debilitating relapses in NMOSD, respectively.  We continue to see that early and ongoing treatment markedly improves outcomes, and we’ll continues to use scientific and real-world insights to improve our understanding and ways to support people living with these neurological disorders.”

Roche to present data from 27 MS studies 

The company will present 27 multiple sclerosis studies that include data showing earlier OCREVUS treatment continues to influence disability progression for around eight years in individuals with primary progressive MS and up to 7.5 years in patients with relapsing MS in the third phase open able trials. In addition, the company will present an updated long-term safety analysis of all clinical studies in RMS  and PPMS patients that will reinforce OCREVUS’ favorable risk-benefit profile.

Roche is focused on addressing health disparities, and the company is optimistic that inclusive research will enhance outcomes and derive insights that can address treatment barriers. The company will present a subgroup analysis of three studies, including CHORDS, ENSEMBLE PLUS, and SaROD in Hispanic, Latino, and African-American populations treated with OCREVUS infusion. Roche is committed to increasing understanding of NMOSD and enhancing care for people living with the condition.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

Trending Stories